Geron Corp
GERN
NASDAQ
Biotechnology
$1.47
USD
-0.07 (-4.23%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.01B
Volume 11.2M
Revenue
$204.56M
TTM
+24.4%
YoY
Gross Margin
95%
TTM
-3.9%
YoY
Net Income
$-67.61M
TTM
+23.2%
YoY
Operating Cash Flow
$-114.38M
TTM
+35.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 49.0 | 47.2 | 48.0 | 51.8 | 57.5 |
YoY Growth | +5459.6% | +67.1% | +1.0% | +30.9% | +17.2% |
Cost of Revenue | 1.2 | 0.0 | 0.0 | 1.7 | 9.2 |
Gross Profit | 47.8 | 47.2 | 48.0 | 50.1 | 48.2 |
Selling, General & Administrative | 38.6 | 39.0 | 41.7 | 35.4 | 38.9 |
Other Operating Expenses | 0.0 | 1.0 | 18.3 | -0.4 | -0.2 |
Total Operating Expenses | 60.3 | 61.1 | 73.6 | 50.0 | 60.7 |
Operating Income | -12.5 | -13.9 | -25.5 | 0.2 | -12.5 |
EBITDA | -12.3 | -13.8 | -8.4 | -0.1 | -12.5 |
Other Income / Expense | -0.1 | -0.2 | -0.1 | -0.1 | -0.0 |
Total Other Income / Expense | -3.9 | -4.5 | -3.3 | -3.8 | -4.2 |
Income Before Income Taxes | -16.4 | -18.4 | -28.9 | -3.6 | -16.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -16.4 | -18.4 | -28.9 | -3.6 | -16.7 |
Consolidated Net Income / Loss | -16.4 | -18.4 | -28.9 | -3.6 | -16.7 |
Net Income Attributable to Common Shareholders | -16.4 | -18.4 | -28.9 | -3.6 | -16.7 |
Basic EPS | -$0.02 | -$0.03 | -$0.04 | -$0.01 | -$0.02 |
Diluted EPS | -$0.02 | -$0.03 | -$0.04 | -$0.01 | -$0.02 |
Basic Shares Outstanding | 666.2M | 667.1M | 667.5M | 669.4M | 670.7M |
Diluted Shares Outstanding | 666.2M | 667.1M | 667.5M | 669.4M | 670.7M |